Evidence map›Paper›PMID 24659544›Full record

ArticleThe European respiratory journal2014

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement.

Christoph Lange, Ibrahim Abubakar, Jan-Willem C Alffenaar, Graham Bothamley, Jose A Caminero, Anna Cristina C Carvalho, Kwok-Chiu Chang, Luigi Codecasa, Ana Correia, Valeriu Crudu and 31 more

Open access · bronzeAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in The European respiratory journal, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 119 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
119citing papers in PubMed, 4 pooled it
25.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

119 citing papers in PubMed, 4 syntheses or guidelines pooled it, 300 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Trial
  6. Review
  7. Article
  8. 80 years of extracellular vesicles: from discovery to clinical translation.Extracellular vesicles and circulating nucleic acids · 2026
    Review
  9. Article
  10. Review
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review

59 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

41 authors at 1 institution in 1 country.

Christoph LangeFor the authors' affiliations see the Acknowledgements section clange@fz-borstel.de.
Ibrahim AbubakarFor the authors' affiliations see the Acknowledgements section.
Jan-Willem C AlffenaarFor the authors' affiliations see the Acknowledgements section.
Graham BothamleyFor the authors' affiliations see the Acknowledgements section.
Jose A CamineroFor the authors' affiliations see the Acknowledgements section.
Anna Cristina C CarvalhoFor the authors' affiliations see the Acknowledgements section.
Kwok-Chiu ChangFor the authors' affiliations see the Acknowledgements section.
Luigi CodecasaFor the authors' affiliations see the Acknowledgements section.
Ana CorreiaFor the authors' affiliations see the Acknowledgements section.
Valeriu CruduFor the authors' affiliations see the Acknowledgements section.
Peter DaviesFor the authors' affiliations see the Acknowledgements section.
Martin DedicoatFor the authors' affiliations see the Acknowledgements section.
Francis DrobniewskiFor the authors' affiliations see the Acknowledgements section.
Raquel DuarteFor the authors' affiliations see the Acknowledgements section.
Cordula EhlersFor the authors' affiliations see the Acknowledgements section.
Connie ErkensFor the authors' affiliations see the Acknowledgements section.
Delia GolettiFor the authors' affiliations see the Acknowledgements section.
Gunar GüntherFor the authors' affiliations see the Acknowledgements section.
Elmira IbraimFor the authors' affiliations see the Acknowledgements section.
Beate KampmannFor the authors' affiliations see the Acknowledgements section.
Liga KuksaFor the authors' affiliations see the Acknowledgements section.
Wiel de LangeFor the authors' affiliations see the Acknowledgements section.
Frank van LethFor the authors' affiliations see the Acknowledgements section.
Jan van LunzenFor the authors' affiliations see the Acknowledgements section.
Alberto MatteelliFor the authors' affiliations see the Acknowledgements section.
Dick MenziesFor the authors' affiliations see the Acknowledgements section.
Ignacio MonederoFor the authors' affiliations see the Acknowledgements section.
Elvira RichterFor the authors' affiliations see the Acknowledgements section.
Sabine Rüsch-GerdesFor the authors' affiliations see the Acknowledgements section.
Andreas SandgrenFor the authors' affiliations see the Acknowledgements section.
Anna ScardigliFor the authors' affiliations see the Acknowledgements section.
Alena SkrahinaFor the authors' affiliations see the Acknowledgements section.
Enrico TortoliFor the authors' affiliations see the Acknowledgements section.
Grigory VolchenkovFor the authors' affiliations see the Acknowledgements section.
Dirk WagnerFor the authors' affiliations see the Acknowledgements section.
Marieke J van der WerfFor the authors' affiliations see the Acknowledgements section.
Bhanu WilliamsFor the authors' affiliations see the Acknowledgements section.
Wing-Wai YewFor the authors' affiliations see the Acknowledgements section.
Jean-Pierre ZellwegerFor the authors' affiliations see the Acknowledgements section.
Daniela Maria CirilloFor the authors' affiliations see the Acknowledgements section.
TBNET
Research Center Borstel - Leibniz Lung Center · DE

Funding

Medical Research Council MC_EX_MR/K011944/1Medical Research Council MC_UP_A900_1122
6 · The paper itself

Abstract

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.

Indexed as

Antitubercular AgentsExtensively Drug-Resistant TuberculosisTuberculosis, Multidrug-ResistantCase ManagementClinical Trials as TopicCommunicable Disease ControlConsensusDisease-Free SurvivalDisease ManagementEuropeGeographyHumansInfectious Disease MedicinePublic HealthRecurrenceTreatment OutcomeAntitubercular Agents

Identifiers

PMID24659544
PMCPMC4076529
OpenAlexW2164091066

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.